Cargando…
COVID-19 in patients with hematologic malignancy
The coronavirus infectious disease (COVID-19) shows a remarkable symptomatic heterogeneity. Several risk factors including advanced age, previous illnesses, and a compromised immune system contribute to an unfavorable outcome. In patients with hematologic malignancy, the immune response to severe ac...
Autores principales: | Langerbeins, Petra, Hallek, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098396/ https://www.ncbi.nlm.nih.gov/pubmed/35544585 http://dx.doi.org/10.1182/blood.2021012251 |
Ejemplares similares
-
Vasculopathy in COVID-19
por: Flaumenhaft, Robert, et al.
Publicado: (2022) -
COVID-19 convalescent plasma
por: Tobian, Aaron A. R., et al.
Publicado: (2022) -
Clinical features of thrombosis and bleeding in COVID-19
por: Thomas, Mari R., et al.
Publicado: (2022) -
Cellular therapies for the treatment and prevention of SARS-CoV-2 infection
por: Conway, Susan R., et al.
Publicado: (2022) -
Reinfection or Reactivation of Coronavirus-19 in Patients with Hematologic Malignancies: Case Report Series
por: Kapoor, Rajan, et al.
Publicado: (2021)